Key references: Risk factors for adverse asthma outcomes

  • Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2017;195(3):302–13. https://www.ncbi.nlm.nih.gov/pubmed/27556234
  • Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: main report. Wisconsin: GINA; 2019. www.ginasthma.org
  • National Asthma Council AustraliaAustralian Asthma Handbook, v2.1. Melbourne: National Asthma Council Australia; 2020. https://www.asthmahandbook.org.au/
  • Patel M, Pilcher J, Reddel HK, Pritchard A, Corin A, Helm C, et al. Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy 2013;43(10):1144–51. https://www.ncbi.nlm.nih.gov/pubmed/24074332
  • Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149(3 Pt 1):604–10. https://www.ncbi.nlm.nih.gov/pubmed/8118625
  • Zeiger RS, Schatz M, Zhang F, Crawford WW, Kaplan MS, Roth RM, et al. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol 2011;128(2):412–4. https://www.ncbi.nlm.nih.gov/pubmed/21807253